Efficacy of Low-Dose BoNT-A Acupoint Injections in Managing Headache, Vertigo, and Allodynia in Vestibular Migraine.

Researchers investigated a novel approach combining acupuncture points with botulinum toxin (Botox) injections to treat vestibular migraine, a condition causing both severe headaches and dizziness. The study followed patients who received low-dose Botox injections at six traditional acupuncture points on the head and neck, including points on the forehead, temples, crown of the head, and base of the skull. Each patient received a total of 50 units of Botox distributed across these specific locations. The treatment was evaluated over six months using standardized questionnaires measuring migraine disability, dizziness impact, vertigo symptoms, and mental health indicators including depression, anxiety, and stress. Results showed statistically significant improvements in all measured areas at both the three-month and six-month follow-up points. Patients experienced reduced headache frequency and severity, decreased dizziness and vertigo symptoms, and improvements in anxiety levels. The benefits of this single treatment session lasted throughout the entire six-month study period. This approach represents an integration of Western pharmaceutical treatment with traditional Chinese medicine acupuncture point theory. For patients suffering from vestibular migraine who haven't found adequate relief with conventional treatments, this combined therapy may offer a promising alternative. The treatment targets both the neurological aspects of migraine and the vestibular symptoms simultaneously. If you're considering this treatment approach, consult with a qualified acupuncturist or neurologist experienced in both botulinum toxin therapy and acupuncture point location.

This prospective study evaluated low-dose Onabotulinum toxin A (50 units total) administered at traditional acupuncture points for vestibular migraine treatment according to Barany Society diagnostic criteria. Injection protocol utilized 5 units/0.1 mL concentration (100 units diluted in 2 mL saline) delivered via 31-gauge needle at six bilateral points: Yintang (EX-HN3), Taiyang (EX-HN5), Baihui (GV20), Shuaigu (GB8), Fengchi (GB20), and Tianzhu (BL10). Six-month follow-up revealed statistically significant improvements (P<.05) across multiple validated instruments at both 3- and 6-month assessments: MIDAS (Migraine Disability Assessment Scale), DHI-S (Dizziness Handicap Inventory-Screening), VSS-SF (Vertigo Symptom Scale-Short Form), and DASS-21 (Depression Anxiety Stress Scale). ASC-12 (Allodynia Symptom Checklist) was also administered. Clinical takeaway: Acupoint-guided BoNT-A injection at substantially lower doses than standard PREEMPT protocol demonstrates sustained efficacy for vestibular migraine, offering a therapeutic option integrating traditional acupuncture point theory with neuromodulation. Sample size and effect sizes were not specified in the abstract.